Arrakis Therapeutics is a biopharmaceutical company developing oral medicines that target RNA to treat a range of diseases. The company is based in Waltham, Massachusetts, and was founded in 2015 by Jennifer Petter, now the company's Chief Innovation Officer. In October 2016, Michael Gilman, a former Biogen executive, was named CEO. In 2017, the company raised a $38 million investment from venture capital firm Canaan Partners as well as Celgene and Pfizer. Arrakis was founded to focus on purposefully discovering RNA-targeting small molecule drugs. Other companies had previously discovered drugs based on RNA-targeting small molecules, however, they were found opportunistically. More information...
According to PR-model, arrakistx.com is ranked 3,876,821st in multilingual Wikipedia, in particular this website is ranked 2,066,945th in English Wikipedia.
The website is placed before sknaquatics.org and after ocmatours.net in the BestRef global ranking of the most important sources of Wikipedia.
